A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer

doi:10.18632/oncotarget.19102

	A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer
	Ge, Long 1,2,3; Tang, Yan 4; Zhang, Qiu-Ning 5; Tian, Jin-Hui 2,3; Wang, Xiao-Hu 4,5; Pieper, Dawid 6; Pan, Bei 7; Li, Lun 8; Ling, Juan 2,3; Bing, Zhi-Tong9
刊名	ONCOTARGET
	2017-08-29
卷号	8 页码:59539-59551
关键词	targeted agents chemotherapy triple-negative breast cancer network meta-analysis randomized controlled trials
ISSN号	1949-2553
DOI	10.18632/oncotarget.19102
英文摘要	Objective: Our network meta-analysis aimed to determine the assistant efficacy of targeted therapy in combined with chemotherapy for advanced/metastatic triple-negative breast cancer (TNBC). Results: A total of 15 randomized controlled trials (RCTs), involving 2,410 patients, met our inclusion criteria. Eight targeted agents involving 11 treatment arms were included. The methodological quality of included RCTs was acceptable. The results of direct comparisons showed that progression-free survival (PFS) was significantly longer with bevacizumab+chemotherapy when compared to chemotherapy alone (hazard ratio [HR] = 0.62, 95% credible intervals [CrI]: 0.41-0.87). However, there were no statistically significant differences for all other direct comparison groups. The results of indirect comparison of different targeted agents revealed no significant differences regarding all outcomes of interest. According to ranking probabilities, all outcomes favored bevacizumab+chemotherapy and veliparib+chemotherapy. Bayesian and Frequentist network meta-analysis showed similar results, and the probability of bias of small-study effects was small. Materials and Methods: A comprehensive literature search in PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science (via ISI Web of Knowledge), BIOSIS Previews (via ISI Web of Knowledge), and Chemical Abstracts (CA) was conducted to identify RCTs involving targeted agents in the treatment of advanced/metastatic TNBC. Two reviewers independently extracted related data and assessed the risk of bias of included studies. Bayesian network meta-analysis was conducted using R-3.3.2 software. Conclusions: Limited evidence showed that targeted agents combined with chemotherapy for advanced/metastatic TNBC were slightly effective. Further investigation of targeted therapies for TNBC is required to improve patient outcomes. The registration number was CRD42014014299.
WOS关键词	RANDOMIZED PHASE-II ; 1ST-LINE TREATMENT ; PROGESTERONE-RECEPTOR ; ESTROGEN-RECEPTOR ; TRIAL ; BEVACIZUMAB ; PACLITAXEL ; CETUXIMAB ; CARBOPLATIN ; SUNITINIB
WOS研究方向	Oncology ; Cell Biology
语种	英语
出版者	IMPACT JOURNALS LLC
WOS记录号	WOS:000408941900132
内容类型	期刊论文
源URL	[http://119.78.100.186/handle/113462/45591]
专题	中国科学院近代物理研究所
通讯作者	Yang, Ke-Hu
作者单位	1.Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China 2.Lanzhou Univ, Evidence Based Med Ctr, Lanzhou 730000, Gansu, Peoples R China 3.Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou 730000, Gansu, Peoples R China 4.Second Peoples Hosp Lanzhou City, Lanzhou 730046, Gansu, Peoples R China 5.Gansu Prov Canc Hosp, Gansu Prov Acad Inst Med Res, Lanzhou 730050, Gansu, Peoples R China 6.Witten Herdecke Univ, Inst Res Operat Med, Sch Med, Fac Hlth, D-51109 Cologne, Germany 7.Lanzhou Univ, Sch Publ Hlth, Lanzhou 730000, Gansu, Peoples R China 8.Cent S Univ, Xiangya Hosp 2, Dept Breast Thyroid Surg, Changsha 410000, Hunan, Peoples R China 9.Chinese Acad Sci, Inst Modern Phys, Lanzhou 730000, Gansu, Peoples R China
推荐引用方式 GB/T 7714	Ge, Long,Tang, Yan,Zhang, Qiu-Ning,et al. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer[J]. ONCOTARGET,2017,8:59539-59551.
APA	Ge, Long.,Tang, Yan.,Zhang, Qiu-Ning.,Tian, Jin-Hui.,Wang, Xiao-Hu.,...&Yang, Ke-Hu.(2017).A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer.ONCOTARGET,8,59539-59551.
MLA	Ge, Long,et al."A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer".ONCOTARGET 8(2017):59539-59551.